晚期非小细胞肺癌免疫治疗的短期疗效及安全性分析
Short-term efficacy and safety analysis of immunotherapy for advanced non-small cell lung cancer
曹敏敏 1潘宇凯1
作者信息
- 1. 江阴市人民医院肿瘤科,江苏江阴 214400
- 折叠
摘要
目的 研究晚期非小细胞肺癌(NSCLC)免疫治疗的短期疗效及安全性.方法 选取江阴市人民医院2022年1月 2023年1月收治的62例NSCLC患者.采用随机数表法分为两组,各31例.对照组行常规化疗,研究组行常规化疗结合免疫治疗.比较两组肿瘤标志物水平、临床疗效及不良反应.结果 治疗前,两组CA199、CEA、SCC水平比较,差异无统计学意(P＞0.05);治疗后,研究组CA199、CEA、SCC水平均较对照组更低,差异有统计学意义(P＜0.05).较之对照组,研究组治疗总有效率更高,差异有统计学意义(P＜0.05).两组不良反应发生率比较,差异无统计学意义(P＞0.05).结论 NSCLC免疫治疗的短期疗效更佳,且安全性良好,可有效提高疾病控制率,控制肿瘤进展.
Abstract
Objective:To study the short-term efficacy and safety of immunotherapy for advanced non-small cell lung cancer(NSCLC).Methods:62 patients with NSCLC from January 2022 to January 2023 in Jiangyin People's Hospital were selected.Randomly divided into two groups,31 cases each.The control group received routine chemotherapy,while the study group received routine chemotherapy combined with immunotherapy.The levels of tumor markers,clinical efficacy and adverse reactions were compared between the two groups.Results:Before treat-ment,there was no significant difference in the levels of CA199、CEA and SCC between two groups(P＞0.05).Af-ter treatment,the levels of CA199、CEA and SCC in the study group were lower than those in the control group,and the difference was statistically significant(P＜0.05).Compared with the control group,the total effective rate in the study group was higher,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:NSCLC immunother-apy has better short-term efficacy and good safety,which can effectively improve the disease control rate and con-trol tumor progression.
关键词
晚期非小细胞肺癌/化疗/信迪利单抗/安全性Key words
Advanced non-small cell lung cancer/Chemotherapy/Sindilimab/security引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据